Treating patients with schizophrenia deficit with erythropoietin?
This systematic review summarizes and critically appraises the literature on the effect of erythropoietin (EPO) in schizophrenia patients and the pathophysiological mechanisms that may explain the potential of its use in this disease. EPO is mainly known for its regulatory activity in the synthesis of erythrocytes and is frequently used in treatment of chronic anemia. This cytokine, however, has many other properties, some of which may improve the symptoms of psychiatric illness. The review follows the preferred reporting items for systematic reviews and meta-analysis (PRISMA) statement guidelines. Three databases (Medline, Web of Science, and Cochrane) were searched combining the search terms 'erythropoietin AND (psychotic disorders OR schizophrenia)'. Seventy-eight studies were included in qualitative synthesis, a meta-analytic approach being prohibited. The findings suggest that several EPO cerebral potential properties may be relevant for schizophrenia treatment, such as neurotransmission regulation, neuroprotection, modulation of inflammation, effects on blood-brain barrier permeability, effects on oxidative stress and neurogenesis. Several potentially detrimental side-effects of EPO therapy, such as increased risk of thrombosis, cancer, increased metabolic rate and mean arterial blood pressure leading to cerebral ischemia could severely limit or halt the use of EPO. Overall, because the available data are inconclusive, further efforts in this field are warranted.
Montpellier University, National Institute for Health and Medical Research, INSERM, Adult Academic Psychiatry Department, La Colombière Hospital/CHRU of Montpellier, Montpellier, France. guillaume.fond@gmail.com
Guillaume
G
Fond
Alexandra
A
Macgregor
Jérome
J
Attal
Aurore
A
Larue
Marie
M
Brittner
Deborah
D
Ducasse
Delphine
D
Capdevielle
D001812:Blood-Brain Barrier; D003072:Cognition Disorders / Q000188:drug therapy* / Q000209:etiology; D004921:Erythropoietin / Q000627:therapeutic use*; D006801:Humans; D007249:Inflammation; D055495:Neurogenesis; D018696:Neuroprotective Agents / Q000627:therapeutic use*; D018384:Oxidative Stress; D012559:Schizophrenia / Q000150:complications / Q000188:drug therapy*
D018696:Neuroprotective Agents; D004921:Erythropoietin